Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for: Schering-Plough

Business
Business
Merck Buys Schering-Plough For $41 Billion - 10 Mar 2009
16 PICTURES
MARKETS-JAPAN-STOCKS/
RTXCKHL
March 10, 2009
People look at a display showing stock prices in downtown Tokyo March 10, 2009. Japan's Nikkei average...
Tokyo, Japan
People look at a display showing stock prices in downtown Tokyo
People look at a display showing stock prices in downtown Tokyo March 10, 2009. Japan's Nikkei average fell 0.7 percent on Tuesday as drugmakers such as Astellas Pharma slid among worries about their global competitiveness after Merck proposed to take over Schering-Plough. REUTERS/Michael Caronna (JAPAN BUSINESS)
MARKETS-JAPAN-STOCKS/
RTXCKHK
March 10, 2009
People crossing the street are reflected in a display showing stock prices in downtown Tokyo March 10,...
Tokyo, Japan
People crossing the street are reflected in a display showing stock prices in downtown Tokyo
People crossing the street are reflected in a display showing stock prices in downtown Tokyo March 10, 2009. Japan's Nikkei average fell 0.7 percent on Tuesday as drugmakers such as Astellas Pharma slid among worries about their global competitiveness after Merck proposed to take over Schering-Plough. REUTERS/Michael Caronna (JAPAN BUSINESS IMAGE OF THE DAY TOP PICTURE)
SCHERINGPLOUGH-MERCK/
RTXCK41
March 09, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said...
Kenilworth, UNITED STATES
A view of the Schering-Plough campus in Kenilworth
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK3Y
March 09, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said...
Kenilworth, UNITED STATES
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. ÊREUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2X
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2R
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. ÊREUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2M
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2I
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK23
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH IMAGE OF THE DAY TOP PICTURE)
SCHERINGPLOUGH-MERCK/
RTXCK1V
March 09, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said...
Kenilworth, UNITED STATES
A view of the Schering-Plough campus in Kenilworth
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH IMAGE OF THE DAY TOP PICTURE)
SCHERINGPLOUGH MERCK/
RTXCJUL
March 09, 2009
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co...
New York, UNITED STATES
A sample of the drug Singulair
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS)
SCHERINGPLOUGH MERCK/
RTXCJUJ
March 09, 2009
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co...
New York, UNITED STATES
A sample of the drug Singulair
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS)
SCHERINGPLOUGH MERCK/
RTXCJUH
March 09, 2009
A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck...
New York, UNITED STATES
A sample of the drug Nasonex
A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH)
SCHERINGPLOUGH MERCK/
RTXCJUF
March 09, 2009
A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck...
New York, UNITED STATES
A sample of the drug Proventil
A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH)
SCHERINGPLOUGH MERCK/
RTXCJUB
March 09, 2009
A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck...
New York, UNITED STATES
A sample of the drug Nasonex
A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS)
SCHERINGPLOUGH MERCK/
RTXCJU5
March 09, 2009
A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. ...
New York, UNITED STATES
A sample of the drug Nasonex made by the Schering Corporation
A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCJPF
March 09, 2009
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this...
New York, UNITED STATES
File photo of Richard Clark, Chairman and C.E.O. of Merck speaking at the Reuters Health Summit in New...
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file photo taken November 19, 2008. Merck & Co Inc. said on March 9, 2009 that it would acquire Schering-Plough Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Brendan McDermid/Files (UNITED STATES BUSINESS HEALTH SCI TECH HEADSHOT)
SCHERINGPLOUGH-MERCK/
RTXCJPA
March 09, 2009
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this...
New York, UNITED STATES
File photo of Richard Clark, Chairman and C.E.O. of Merck speaking at the Reuters Health Summit in New...
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file image taken November 19, 2008. Merck & Co Inc. said on March 9, 2009 that it would acquire Schering-Plough Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Brendan McDermid/Files (UNITED STATES BUSINESS HEADSHOT HEALTH SCI TECH)
SUMMIT-HEALTH/
RTXAGS
November 13, 2007
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November...
New York, UNITED STATES
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November 13, 2007. REUTERS/Brendan McDermid (UNITED STATES)
SUMMIT-HEALTH/
RTXAGO
November 13, 2007
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November...
New York, UNITED STATES
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November 13, 2007. REUTERS/Brendan McDermid (UNITED STATES)
SUMMIT-HEALTH/
RTXAGI
November 13, 2007
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November...
New York, UNITED STATES
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York
Fred Hassan, CEO of Schering-Plough Corp., speaks at the Reuters Health Summit in New York, November 13, 2007. REUTERS/Brendan McDermid (UNITED STATES)
HASSAN
RTXMBJU
November 21, 2003
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003 during the Reuters Health Summit...
New York, USA
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003 during the Reuters Health .....
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003 during the Reuters Health Summit in New York City.
RTRS20N
November 21, 2003
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health...
UNITED STATES
SCHERING-PLOUGH CEO FRED HASSAN SPEAKS IN NEW YORK.
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health Summit in New York. REUTERS/Jeff Christensen

JC
RTR7HJ2
November 21, 2003
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health...
UNITED STATES
SCHERING-PLOUGH CEO FRED HASSAN SPEAKS IN NEW YORK.
Fred Hassan, CEO of Schering-Plough, talks to reporters November 21, 2003
during the Reuters Health Summit in New York City. REUTERS/Jeff Christensen

JC
Sort by
Display
Items per page
Page
of 1